Insights & news

European Commission Continues to Pursue "Gun Jumping" Merger Control Proceedings against Illumina and Grail

  • 19/07/2022
  • Articles

On 20 August 2021, the European Commission (the Commission) said that it would investigate whether Illumina’s decision, made public on 18 August 2021, to acquire Grail pending the Commission’s review of that transaction under Regulation 139/2004 on the control of concentrations between undertakings (the Merger Regulation) is in breach of the “standstill obligation” provided for by Article 7, Merger Regulation. Pursuant to this provision, a concentration notifiable under the Merger Regulation must not be implemented until after the Commission has approved it (see, Van Bael & Bellis Life Sciences News and Insights of 24 August 2021).

Today, the Commission published a press-release indicating that it sent a Statement of Objections (SO) to Illumina and Grail because it continues to be of the opinion that these firms breached Article 7 by implementing the transaction prior to the conclusion of the Commission's investigation of that transaction. If the Commission’s at this point still preliminary view results in a final decision of the same nature, the Commission will have the power to impose a fine of up to 10% of each company's annual worldwide turnover. The Commission’s SO marks a further, if predictable, step in the procedural war which this transaction has unleashed. Earlier, the Commission had already adopted interim measures in an attempt to avert the possibly irreversible consequences of Illumina’s acquisition of Grail (see, Van Bael & Bellis Life Sciences News and Insights of 29 October 2021).
 
Not coincidentally, the Commission’s position was bolstered by last week’s judgment by the General Court that the Commission was right in asserting jurisdiction over the transaction pursuant to Article 22 of the Merger Regulation (see, Van Bael & Bellis Life Sciences News and Insights of 14 July 2022). That in-depth review is currently suspended.  

Attachments:

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 15/07/2022
    • News

    European Commission Publishes Proposal for Regulation on Substances of Human Origin

    On 14 July 2022, the European Commission (the Commission) published its long-awaited Proposal for a Regulation on standards of quality and safety for substances of human origin intended for human application (COM(2022) 338 final; the proposed Regulation) and an accompanying Q&A document (see, attachments). The proposed Regulation updates the current regulatory framework to improve safety and quality standards applicable to substances of human origin (so-called SoHOs). SoHOs include blood, tissues, cells and any other substances of human origin like human breast milk and microbiota. SoHOs can be directly intended for human application but can also be used in preparations or in manufactured products. Article 2 of the proposed Regulation provides for a list of “SoHO activities” that fall within the scope of the proposed Regulation. The list includes activities such as donor recruitment, processing of SoHOs, distribution, import and export of SoHOs and human application of SoHOs.   The proposed Regulation will apply to all SoHOs. Only solid organs used for transplantation will remain regulated separately under the Organs Directive (Directive 2010/45/EU). In view of the broad definition of the term SoHOs, the proposed Regulation will be future-proof in the sense that it will automatically apply to new substances of human origin that can be applied to patients. A key aspect of the proposed Regulation is that it empowers the Commission to adopt implementing acts regarding patient, donor and offspring protection. However, in the absence of such implementing acts, “SoHO entities” (which are defined in Article 3(24) as “organisation[s] legally established in the Union that carr[y] out one or more of the SoHO activities”) will have to apply standards established by the European Centre for Disease Prevention and Control and the European Directorate for the Quality of Medicines & HealthCare of the Council of Europe. The aim is to ensure that technical rules applicable to SoHO activities remain updated and to avert the accumulation of obsolete rules which would stand in the way of novel SoHO-based treatments and new medical techniques. For purposes of enforcement, the Commission devised a supervision mechanism based on national Competent Authorities. Chapters II and III of the proposed Regulation are dedicated to, respectively, “Competent Authorities” and “SoHO Supervisory Activities”. The rules enable extensive coordination between the different national Competent Authorities and the Commission. According to the Commission, increased harmonisation in the field of SoHO activities between EU countries could bring significant improvements in treatments such as stem, cornea, or skin transplants. Facilitated exchanges of SoHOs could even save lives, especially for conditions like blood cancer for which blood supply is of critical importance. The proposed Regulation will now be discussed by the Council and the European Parliament. Once the final text is agreed, adopted and published, most of the provisions will take effect after a transition period of two years.

    Read more
    • 14/07/2022
    • Articles

    General Court Confirms European Commission's Power to Review Illumina-Grail Even Though EU and National Turnover Thresholds Are Not Reached

    Yesterday, the General Court of the European Union came down on the side of the European Commission (the Commission) in that agency’s dispute with genomics firm Illumina and held that the Commission has jurisdiction to examine Illumina's acquisition of cancer detection test start-up Grail, even though the transaction escapes the European and Member State turnover thresholds for review (case T-227/21, Illumina, Inc. v. European Commission – see, attachment).

    Read more
    • 11/07/2022
    • Articles

    Belgium - New Royal Decree Allows Pharmacist to Replace Unavailable Prescription Medicine by Alternative

    On 8 July 2022, the Belgian Official Journal published a Royal Decree of 3 July 2022 establishing the conditions and terms of substitution by the pharmacist in case of unavailability of a prescribed medicine which is being delivered in a public officina (Koninklijk Besluit van 3 juli 2022 tot vaststelling van de voorwaarden en modaliteiten van de substitutie door de apotheker in geval van onbeschikbaarheid van een voorgeschreven geneesmiddel dat wordt afgeleverd in een voor het publiek opengestelde officina/Arrêté royal du 3 juillet 2022 fixant les conditions et modalités de la substitution par le pharmacien en cas d'indisponibilité d'un médicament prescrit qui est délivré en officine ouverte au public) (the RD; see, attachment).

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *